Bunch of executive appointments at Sanofi
Olivier Brandicourt, chief executive of French pharma major Sanofi (Euronext: SAN), announced today a number of changes to the company's executive committee, supporting Sanofi's recently announced 2020 Strategic Roadmap.
As of June 1, 2016, the company's executive committee, chaired by Dr Brandicourt, will be comprised of the following members:
- Olivier Charmeil, executive vice president and general manager, general medicines and emerging markets;
- Jérôme Contamine, executive VP, finance,
- Peter Guenter, executive VP and general manager, diabetes & Cardiovascular;
- Carsten Hellmann, executive VP and general manager of Merial (until December 31, 2016). He has accepted a position as President and CEO of ALK but will stay with Sanofi until the end of the year to support the strategic business swap project with Boehringer Ingelheim;
- Karen Linehan, executive VP, legal affairs and general counsel;
- David Loew, executive VP and general manager of Sanofi Pasteur;
- Philippe Luscan, executive VP, global industrial affairs;
- Muzammil Mansuri, PhD, executive VP, strategy & business development;
- David Meeker, MD, executive VP and general manager of Sanofi Genzyme;
- Ameet Nathwani, MD, executive VP, medical affairs;
- Roberto Pucci, executive VP, human resources; and
- Elias Zerhouni, MD, president, global research & development.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze